Bristol-Myers Squibb Company

BMY

US1101221083

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

06:59am - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

48.86 USD

Average target price

56.2 USD

Spread / Average Target

+15.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-12.12%	99.03B
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.58%	358B
MERCK & CO., INC.	+19.16%	322B
ABBVIE INC.	+7.65%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-11.34%	149B
AMGEN INC.	-6.94%	146B

Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 12:30:52 2024-04-25 pm EDT			5-day change	1st Jan Change
44.62 ^USD	-8.69%		-6.65%	-12.12%

05:43pm	Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco...
05:04pm	Stocks in motion: Large caps struggle

Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco...	11:43am
Stocks in motion: Large caps struggle	11:04am
Trending : Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts	10:39am	DJ
The specter of stagflation rears its ugly head again	09:21am
Bristol Myers Shedding 2,200 Jobs in Cost Savings Push	08:52am	DJ
Bristol-Myers Squibb Swings to Q1 Non-GAAP Loss, Revenue Rises; Provides 2024 Guidance	08:08am	MT
Bristol Myers: heavy quarterly loss on charges	08:08am	CF
Transcript : Bristol-Myers Squibb Company, Q1 2024 Earnings Call, Apr 25, 2024	08:00am
Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss	07:53am	DJ
(BMY) BRISTOL MYERS SQUIBB Sees Fiscal Year 2024 EPS Range $0.40 - $0.70	07:35am	MT
Earnings Flash (BMY) BRISTOL MYERS SQUIBB Posts Q1 Revenue $11.87B, vs. Street Est of $11.45B	07:35am	MT
Futures Decline Pre-Bell Ahead of Earnings, Economic Reports; Asia Churns, Europe Down	07:02am	MT
Bristol-Myers Squibb Company Reports Earnings Results for the First Quarter Ended March 31, 2024	06:59am	CI
Bristol Myers posts quarterly loss, revenue rises 5%	06:59am	RE
Futures falter as Meta Platforms weighs on megacaps	06:03am	RE
Germany's Evotec appoints Christian Wojczewski as CEO	Apr. 23	RE
Novartis Nominates Former Bristol Myers Squibb CEO as New Chair	Apr. 23	MT
Novartis Lifts 2024 Guidance as First-quarter Earnings Grow on Strong Blockbuster Drug Demand	Apr. 23	MT
Novartis raises targets for 2024	Apr. 23	CF
Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates	Apr. 22	RE
Bristol-Myers Squibb Signs $380 Million Deal With Cellares to Manufacture CAR T Cell Therapies	Apr. 22	MT
Bristol Myers signs $380 mln CAR-T therapies supply deal with Cellares	Apr. 22	RE
Bristol Myers signs supply agreement with Cellares	Apr. 22	CF
Bristol Myers Squibb and Cellares reach $380 mln supply deal for CAR-T therapies	Apr. 22	RE
Bristol Myers Squibb and Cellares Announce Worldwide Capacity Reservation and Supply Agreement for Manufacture of CAR T Cell Therapies	Apr. 22	CI